Ocular Therapeutix Yönetim

Yönetim kriter kontrolleri 1/4

Ocular Therapeutix CEO'su Pravin Dugel, Apr2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.096% doğrudan sahiptir ve bu hisselerin değeri € 1.23M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 5.5 yıldır.

Anahtar bilgiler

Pravin Dugel

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

Pravin Dugel (60 yo)

less than a year

Görev süresi

Dr. Pravin U. Dugel, M. D. has been Executive Chairman of Ocular Therapeutix, Inc. since February 2024 and also serves as its Chief Executive Officer and President since April 15, 2024. He served as Presid...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Donald Notman	CFO, COO & Principal Accounting Officer	7.3yrs	US$1.34m	0.051% € 659.6k
Jeffrey Heier	Chief Scientific Officer	less than a year	US$329.90k	0.049% € 632.2k
Pravin Dugel	Executive Chairman	less than a year	Veri yok	0.096% € 1.2m
Peter Jarrett	Chief Technology Officer	no data	Veri yok	Veri yok
William Slattery	Vice President of Investor Relations	no data	Veri yok	Veri yok
Todd Anderman	Chief Legal Officer & Corporate Secretary	no data	Veri yok	Veri yok
William Ransone	Vice President of Global Sales & Marketing	no data	Veri yok	Veri yok
Barry Rubenstein	Chief Human Resources Officer	less than a year	Veri yok	Veri yok
Steve Meyers	Chief Commercial Officer	1.9yrs	Veri yok	Veri yok
Peter Kaiser	Chief Development Officer	less than a year	Veri yok	0.014% € 175.0k
Sanjay Nayak	Chief Strategy Officer	less than a year	Veri yok	0.11% € 1.4m
Nadia Waheed	Chief Medical Officer	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: 0OT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pravin Dugel	Executive Chairman	less than a year	Veri yok	0.096% € 1.2m
Charles Warden	Lead Independent Director	16.9yrs	US$303.61k	0.031% € 395.9k
Merilee Raines	Independent Director	3.3yrs	US$263.61k	0.013% € 170.9k
Richard Lindstrom	Independent Director	12.1yrs	US$261.11k	0.096% € 1.2m
Adrienne Graves	Independent Director	1.4yrs	US$397.89k	0.0051% € 65.4k
Leslie Williams	Independent Director	5.8yrs	US$261.11k	0.016% € 207.8k
Seung Hong	Independent Director	5.5yrs	US$248.61k	0.013% € 170.9k

5.5yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0OT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 13:18
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Ocular Therapeutix, Inc. 21 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Colleen Kusy	Baird
Anita Dushyanth	Berenberg
Tazeen Ahmad	BofA Global Research

Ocular Therapeutix Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ocular Therapeutix, Inc. Appoints Namrata Saroj, OD, as Chief Business Officer

Executive Chairman recently sold €168k worth of stock

Executive Chairman recently sold €116k worth of stock

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Management Changes

Recent updates

Ocular Therapeutix Announces More Than 300 Subjects Randomized in Sol-1

New minor risk - Insider selling

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.006 loss in 3Q 2023)

Ocular Therapeutix, Inc. Appoints Namrata Saroj, OD, as Chief Business Officer

Ocular Therapeutix, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Ocular Therapeutix, Inc. Announces Accelerated Timelines for Sol-1 Registrational Trial of AXPAXLI in Wet AMD

Now 22% undervalued

Now 23% undervalued

Executive Chairman recently sold €168k worth of stock

Second quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 2Q 2023)

Ocular Therapeutix, Inc. Announces Fda Feedback That Sol-R Trial Is Appropriate as A Registrational Study in Wet Amd

Ocular Therapeutix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Ocular Therapeutix, Inc. Announces First Patients Enrolled in Phase 3 Sol-R Wet AMD Study

Executive Chairman recently sold €116k worth of stock

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.39 loss in 1Q 2023)

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

New major risk - Shareholder dilution

Full year 2023 earnings released: US$1.01 loss per share (vs US$0.92 loss in FY 2022)

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Ocular Therapeutix, Inc. Announces Management Changes

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

President recently sold €84k worth of stock

Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

New minor risk - Profitability

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.006 loss per share (vs US$0.31 loss in 3Q 2022)

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.24 loss in 2Q 2022)

Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member

New major risk - Share price stability

Ocular Therapeutix, Inc. Completes Enrollment of the Helios Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

Ocular Therapeutix, Inc. Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.16 loss in 1Q 2022)

Full year 2022 earnings released: US$0.92 loss per share (vs US$0.086 loss in FY 2021)

Ocular Therapeutix™ Announces Interim 10-Month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Insufficient new directors

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.035 profit in 3Q 2021)

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Ocular Therapeutix, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Ocular Therapeutix, Inc. Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.11 loss in 2Q 2021)

Insufficient new directors

Ocular Therapeutix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Ocular Therapeutix, Inc. Announces Executive Changes

Ocular Therapeutix, Inc. Announces Executive Changes

First quarter 2022 earnings released: US$0.16 loss per share (vs US$0.041 profit in 1Q 2021)

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2022

Ocular Therapeutix, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Ocular Therapeutix, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Ocular Therapeutix, Inc. Announces Resignation of Bruce A. Peacock as Member of the Board of Directors

Third quarter 2021 earnings released: EPS US$0.035 (vs US$0.19 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.64 loss in 2Q 2020)